Skip to main content Skip to search Skip to main navigation

How to implement ICH Q3D of elemental impurities in 5 steps (free manual)

0 reviews

Average rating of 0 out of 5 stars

Leave a review!

Share your experiences with other customers.

Product Information

Why do you need an elemental impurities risk assessment?

As of June 2016, all new medicinal products have to be evaluated based on the ICH guideline Q3D on elemental impurities. As of December 2017, this guideline came into effect for already authorised medicinal products as well. Therefore, every authorised medicinal product has to be evaluated.

How to obtain an elemental impurities risk assessment?

The proven and successful collaboration between Dalia and GMP-Verlag Peither AG provides you with an economically priced alternative to conventional elemental impurities risk assessments. Following verification of the critical key data, we will be pleased to send you a binding, fixed price quote.

Our service includes:

  • Issuing of the elemental impurities risk assessment
    • according to ICH Q3D guideline in English
    • issued for the specific medicinal product according to ICH Q3D guideline
    • issued by European toxicological experts

This is what we need from you to prepare a binding, fixed price quote

  • Company name and address
  • Name of the medicinal product
  • Completed questionnaire
Request a quote

Do you Have any Questions?

Talk to our customer advisors

Do you have any questions about our products and services? We are here to help.

Customer Reviews

0 reviews

Average rating of 0 out of 5 stars

Leave a review!

Share your experiences with other customers.

You may Also be Interested in the Following Products

Skip product gallery

y

Elemental Impurities Risk Assessment | Sample Document

Elemental Impurities Risk Assessment | Sample Document

Why do you need an elemental impurities risk assessment? As of June 2016, all new medicinal products have to be evaluated based on the ICH guideline Q3D on elemental impurities. As of December 2017, this guideline came into effect for already authorised medicinal products as well. Therefore, every authorised medicinal product has to be evaluated. How to obtain an elemental impurities risk assessment? The proven and successful collaboration between Dalia and GMP-Verlag Peither AG provides you with an economically priced alternative to conventional elemental impurities risk assessments. Following verification of the critical key data, we will be pleased to send you a binding, fixed price quote. Request a quote Our service includes Issuing of the elemental impurities risk assessment According to ICH Q3D guideline in English Issued for the specific medicinal product according to ICH Q3D guideline Issued by European toxicological experts This is what we need from you to prepare a binding, fixed price quote Company name and address Name of the medicinal product Request a quote

delivery time appr. 2-5 workdays after receipt of payment
€0.00 net excl. VAT

Recommended Articles

EC: EU and WHO Strengthen Cooperation on Pandemic Intelligence for Medical Countermeasures

EC: EU and WHO Strengthen Cooperation on Pandemic Intelligence for Medical Countermeasures

“Today public health faces a new kind of challenge: speed. Diseases move faster and are more unpredictable than ever, racing across borders and continents.”, said Hadja Lahbib, Commissioner for Equality, Preparedness and Crisis Management, upon signing an EU4Health contribution agreement worth over 4 million euros with the World Health Organisation’s (WHO) Hub for Pandemic and Epidemic Intelligence in Berlin on 24 July 2026.

Read more
PIC/S: Revised Recommendations on Qualification and Validation

PIC/S: Revised Recommendations on Qualification and Validation

PIC/S has published a fundamentally revised version of its “Recommendations on Qualification and Validation” (PI 006-4). The new document was issued on 30 July 2026, will enter into force on 1 October 2026, and replaces the 2007 edition. The revised document has been expanded from 26 to 49 pages.
Read more
How do Components like Filling Needles and Laminarisators Affect First Air Integrity?

How do Components like Filling Needles and Laminarisators Affect First Air Integrity?

Here's the answer:
Read more
Smart Strategies for Handling Indirect Product Contact Components

Smart Strategies for Handling Indirect Product Contact Components

Aseptic filling processes: Handling indirect product contact parts in compliance with the revised Annex 1 of the EU GMP Guide.
Read more
Swissmedic: Implementation of New EU GMP Implementing Regulations for Veterinary Medicinal Products

Swissmedic: Implementation of New EU GMP Implementing Regulations for Veterinary Medicinal Products

The new EU Implementing Regulations on GMP requirements for veterinary medicinal products and active substances will not be automatically transposed into the Swiss Medicinal Products Licensing Ordinance (MPLO) on 16 July 2026. Swissmedic has confirmed that, although the structure of the new EU legislation has changed, the underlying GMP requirements remain largely unchanged.
Read more
EU: Annexes 4 and 5 no Longer Included in the EU GMP Guide

EU: Annexes 4 and 5 no Longer Included in the EU GMP Guide

Following the entry into application of Commission Implementing Regulations (EU) 2025/2091 and (EU) 2025/2154 on the principles and guidelines of Good Manufacturing Practice (GMP) for veterinary medicinal products and active substances for veterinary medicinal products on 16 July 2026, the European Commission removed Annexes 4 and 5 from the EU GMP Guide.
Read more
EMA: Revision of Annex 15 Delayed

EMA: Revision of Annex 15 Delayed

In February 2026, the EMA published a concept paper on the revision of Annex 15 "Qualification and Validation" of the EU GMP Guide (we reported previously). The Agency has now released a corrected version containing a significantly revised timetable.
Read more
EU: Updated Q&A on Safety Features for Human Medicinal Products

EU: Updated Q&A on Safety Features for Human Medicinal Products

The European Commission has published Version 22 of its Questions and Answers on Safety Features for Medicinal Products for Human Use.
Read more
EMA: Q&A Paper on Measures to Prevent Microbial Contamination of Non-Sterile Medicinal Products

EMA: Q&A Paper on Measures to Prevent Microbial Contamination of Non-Sterile Medicinal Products

The EMA has published a new Q&A paper on technical and organisational measures to prevent microbial contamination of non-sterile medicinal products.
Read more
Why is import authorisation necessary for medicinal products entering the EU?

Why is import authorisation necessary for medicinal products entering the EU?

Here's the answer:
Read more
When APS Fail and First Air is at Risk

When APS Fail and First Air is at Risk

At the PDA Good Aseptic Manufacturing Conference 2026, Alberto Gonzales (Takeda) discussed challenges and practical solutions related to aseptic process simulations (APS). Anna Campanella (Takeda) and Hussein Bachir (Franz Ziel) explored how first air protection in aseptic processing can be compromised by equipment design, glove interventions, and operator activities.
Read more
FDA: Updated Compliance Program for Preapproval Inspections

FDA: Updated Compliance Program for Preapproval Inspections

The FDA has revised its Compliance Program 7346.832, “Preapproval Inspections”. The updated program describes the planning, conduct and evaluation of preapproval inspections (PAIs) for New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs).
Read more
Previous
Next